Isoray’s Blu Build Intraoperative Loader is the first single-use, disposable device for modern brachytherapy exclusively using Cesium Blu seeds.
Blu Build allows clinicians to build custom strands in real-time while in the operating room. Real-time stranding provides a flexible treatment solution for a variety of clinical approaches without a significant impact to procedural time.
Now available for qualified clinicians.
Blu Build Custom Strands
Seamlessly create custom strands intraoperatively.
Easily select between Cesium Blu seeds and bio-absorbable spacers to build a custom strand in any desired sequence.
Confirm each custom-built sequence and seamlessly strand them into the proprietary bio-absorbable sleeve.
Use the cutting tool, scissors or a scalpel to trim the strand, removing the sleeve cap.
Transfer your customized strand directly into the needle, or relay device, for implant.
A powerful new platform for any brachytherapist.
- 9.7 day half-life
- Energy level at 30.4 Kev
- Faster dose delivery rate. 90% of dose delivered in ~33 days
- Detectable in the body for only 97 days
- Single-use, disposable device
- No maintenance or in-servicing required
- Capable device that supports a variety of techniques
- No capital investment (included in seed order cost)
- Elegant 3D printed design for ease of use and quick training
- No power needed
- No on-site sterilization needed
- Mick Cartridge compatible
- Expert Sales and Support teams ensuring real-time ordering and delivery for procedures throughout the body.
- Committed to offering interactive training programs throughout the US teaching the leading techniques and the newest tools.
- Empowering patients to make their own treatment decisions based on decades of data.
Modern brachytherapy starts here.
Not all brachytherapy radioisotopes are the same. Cesium Blu, Cs-131, offers you a powerful option for treating prostate and other cancers throughout the body.
Isoray’s proprietary isotope, Cesium Blu, has a higher energy allowing for a more uniform dose distribution with less overdosing than other permanent isotopes. (1)
Isoray’s proprietary isotope, Cesium Blu, has a shorter half-life than other commonly used isotopes for the treatment of cancer throughout the body, resulting in a shorter duration of radiation which contributes to a rapid resolution of patient side effects. (2)
Improved Coverage of the Prostate
Isoray’s Cesium Blu proprietary permanent prostate cancer brachytherapy seeds allow for better dose homogeneity and the sparing of the urethra and rectum while providing comparable prostate coverage compared to other seeds with comparable or fewer seeds and needles. (3, 4, 5, 6)
Rapid Resolution of Side effects
Isoray’s proprietary isotope, Cesium Blu, has a shorter half-life than other commonly used isotopes for the treatment of cancer throughout the body, resulting in a shorter duration of radiation which contributes to a rapid resolution of patient side effects. (7, 8, 9, 10)
Higher Biologically Effective Dose
Isoray’s Cesium Blu also delivers a higher “biological effective dose” or BED compared to I-125 or Pd-103 across a wide range of tumor types. (11)
Isoray along with investigators tracking PSA in both single arm and randomized prostate cancer treatment trials have concluded that Cesium Blu’s PSA response rates have similar early tumor control to I-125, which was previously considered the gold standard in permanent seed brachytherapy. (8, 12, 13)
Your Isotope Choice Makes a Difference
Cesium BluIntroduced in 2004
9.7 Day Half-Life
- The amount of time for the radiation to half. A shorter half life means quicker to PSA baseline. (8, 12, 13)
- The energy level of the isotope. Higher energy leads to greater coverage of the infected organ.
33 Days for 90% Dose
- Faster dose delivery rate.
Detectable in the body for 97 Days
Paladium-103Introduced in 1986
17 Day Half Life (18)
58 Days for 90% Dose
Detectable in the body for 170 Days
Iodine-125Introduced in 1965
60 Day Half Life (18)
204 Days for 90% Dose
Detectable in the body for 600 Days
Armpilla C, Dale R, Coles I, et al. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Rad Onc Biol Phys 2003; 55:378-385.